Desmoid Tumors Market - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030
Desmoid Tumors |
A rare condition is the Desmoid Tumors. Fibroblasts are the cells that give
rise to desmoid tumours. These cells can be found all over the body and play a
critical part in wound healing in addition to provide structural support and
protection. These tumours can happen at any age, although being most frequently
discovered in women in their twenties and thirties. They may develop slowly or
turn cancerous. Aggressive fibromatosis, however, might result in fatal
consequences and other major issues. It is a specific type of illness that puts
pressure on important organs like the intestines. There are some cases that are
related to familial FAB polyposis, even if the majority of cases are not
problematic. About 10% of people with Gardner's syndrome have Desmoid Tumors.
Global Desmoid Tumors Market is estimated to be valued at US$
2,494.1 million in 2022 and is expected to exhibit a CAGR of 7.3% during the
forecast period (2022-2030).
Drug development for the treatment of desmoid tumours is the
primary focus of major Desmoid
Tumors Market participants, and this strategy is anticipated to fuel
market expansion over the coming years. For instance, in July 2022, Ayala
Pharmaceuticals, Inc., a clinical-stage oncology company, released encouraging
interim results from Part A of the ongoing RINGSIDE Pivotal Phase 2/3 clinical
study evaluating AL102 in desmoid tumours. The study is evaluating AL102 in
patients with uncommon tumours and aggressive cancers.
AL102 is a potent and highly targeted GSI that is taken
orally. Also, the existence of a desmoid tumour foundation, which provides
funding for research into desmoid tumours, is anticipated to fuel market
expansion in the nation over the coming years. For instance, the Desmoid Tumour
Foundation of Canada (DFC) is a charitable organisation with the goal of
sponsoring desmoid tumour research in Canada. DFC is committed to supporting Desmoid Tumors Market research and developing a treatment for this uncommon
illness. DFC encourages research teams from various institutions to work
together to discover treatments more quickly.
Drug Types:
·
Non-steroidal
anti-inflammatory drugs (NSAIDs)
·
Targeted
Therapy
·
Chemotherapy
·
Hormone
Therapy
·
Others
Distribution Channel:
·
Hospital
Pharmacy
·
Retail
Pharmacy
·
Online
Pharmacy
Major Companies
involved are Horizon
Therapeutics Plc, Strides Pharma Science Limited, Teva Pharmaceutical
Industries Ltd., Amneal Pharmaceuticals LLC, Hikma Pharmaceuticals PLC, Natco Pharma Ltd, Lupin,
Zydus Lifesciences, Mylan N.V.,
Assertio Holdings, Inc., Mayne
Pharma Group Limited, Alembic Pharmaceuticals Limited, Aprazer, Ayala Pharmaceuticals, SpringWorks Therapeutics, Inc., Iterion Therapeutics, Novartis AG, Apotex
Inc., Bayer AG., Sun Pharmaceutical
Industries Ltd, Dr. Reddy’s Laboratories Ltd., Endo International plc, Abbott,
and Getwell Pharmaceuticals
Comments
Post a Comment